Ib-U-Ron (Ibuprofen)

Ibuprofen blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which decreases the synthesis of prostaglandins. Lower prostaglandin levels reduce pain signalling, lower the hypothalamic temperature set‑point, and limit the inflammatory response, providing analgesic, antipyretic, and anti‑inflammatory effects.

The appropriate dose of Ib-U-Ron is determined by the prescribing healthcare professional based on the patient’s age, weight, clinical condition and treatment goals. Dosage may vary, and patients should follow the prescriber’s instructions without self‑adjusting the amount or frequency.

Ib-U-Ron should be avoided in the third trimester of pregnancy because ibuprofen may affect fetal cardiovascular development. Use during the first two trimesters or while breastfeeding should only be considered if the potential benefit outweighs the risk and after consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Ib-U-Ron product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Ib-U-Ron delivers ibuprofen, a well‑studied NSAID with a balanced COX‑1/COX‑2 inhibition profile. Compared with selective COX‑2 inhibitors, ibuprofen has a slightly higher risk of gastrointestinal irritation but a lower cardiovascular risk. Its rectal formulation offers an alternative route for patients who cannot take oral medications.

Store Ib-U-Ron at temperatures below 25 °C (77 °F). Keep the suppositories in their original packaging, protect them from moisture, direct sunlight and excessive heat to maintain product stability and potency.

Ib-U‑Ron is inserted rectally. The patient should lie on their side with the lower leg drawn toward the abdomen, gently push the suppository into the rectum using a gloved finger, and remain in that position for a few minutes to ensure proper absorption.

Serious risks include gastrointestinal bleeding or ulceration, acute kidney injury, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and cardiovascular events like myocardial infarction or stroke. Patients should seek immediate medical attention if they notice signs such as black stools, sudden loss of kidney function, rash with blistering, or chest pain.

Ib-U‑Ron should not be used by individuals with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal ulceration or bleeding, patients with severe renal or hepatic impairment, and women in the third trimester of pregnancy. Consultation with a healthcare professional is essential for anyone with underlying health conditions.